Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received approval from the National Medical Products Administration for the marketing application of its product, Ibuprofen Arginine. This approval allows the company to register the product, which is used for treating various types of pain and fever, and is part of the Class B variety in China’s National Drug Catalogue. The approval is expected to enhance the company’s market presence and potentially increase its sales in China’s public medical institutions.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of chemical substance drugs. The company is involved in the pharmaceutical industry, with a market focus on domestic production of chemical raw materials.
Average Trading Volume: 4,889,496
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.26B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.